Rates of increase of antibiotic resistance and ambient temperature in Europe: a cross-national analysis of 28 countries between 2000 and 2016
Just published in Eurosurveillance – Europe’s journal on infectious disease surveillance, epidemiology, prevention and control
Click link below for details
Jointly organised by the BSAC and GARDP. For 2021, the conference collaborators are the Helmholtz Institute for Pharmaceutical Sciences (HIPS), the German Center for Infection Research (DZIF) and the International Research Alliance for Antibiotic Discovery and Development (IRAADD) (a JPIAMR funded network)
Free to Register. Click link below for Full Programme and Registration
Link for ACC2021
This report presents the results of the first multi-country and multi-professional study on the knowledge, attitudes and behaviours of healthcare workers regarding antibiotics, antibiotic use and antibiotic resistance across 30 European Union (EU) and European Economic Area (EEA) countries. While several studies have assessed the knowledge, attitudes and behaviours of the general public, healthcare students and individual professional groups in EU Member States, there is a lack of literature on the topic which considers the full breadth of healthcare workers.
Antimicrobial resistance in European medical schools contributes to enhancing education on antimicrobial resistance in medical schools in Europe. By increasing AMR awareness amongst future medical doctors, we can help curb inappropriate antimicrobial prescriptions, and reduce antimicrobial residues in the environment and exposures to AMR.
Based on interviews with 150 experts from the public health, policy and scientific communities, this report gives an update on the status quo, recent developments and remaining critical gaps in the AMR response globally.
European Antibiotic Awareness Day (EAAD) takes place on Wednesday 18 November 2020, in partnership with the World Health Organisation’s (WHO) World Antimicrobial Awareness Week (18 – 24 November 2020). EAAD is a European initiative that aims to raise awareness about the threat to public health of antibiotic resistance, and the importance of prudent antibiotic use. The latest available data confirms that across the European Union the number of patients infected by resistant bacteria is increasing and that antibiotic resistance is a major threat to public health.
Irish Government Events
18 – 24 November 2020
World Antimicrobial Awareness Week (WAAW) aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of drug-resistant infections.
Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, and parasites resist the effects of medications, making common infections harder to treat and increasing the risk of disease spread, severe illness and death. Antimicrobials are agents that are critical tools for fighting diseases in humans, animals and plants and include antibiotic, antiviral, antifungal and antiprotozoal medicines. Multiple factors – including overuse of medicines in humans, livestock, and agriculture, as well as poor access to clean water, sanitation and hygiene – have accelerated the threat of antimicrobial resistance worldwide.
Click Link: WAAW
Pfizer Healthcare Ireland in collaboration with RCSI and AMR Ireland
bring you a free-of-charge event
‘AMR: Can we change a resistant culture?’
on 19th November 2020, 19:00-21:00
Click link for Details and Registration: AMR Event
AMR Stakeholder Network (European Public Health Alliance)
Three online discussions in the run up to European Antibiotic Awareness Day hosted by the MEP Interest Group on AMR to raise awareness of the need for action, and find evidence-informed policy solutions to this urgent threat to human, animal and environmental health.
Take part in the debate and discuss what can can be done to boost actions to tackle AMR at EU level.
Webinar 1 – 13th November 2020: AMR in the Environment: From Monitoring to Action
Webinar 2 – 16th November 2020: Tackling the dependence of EU food systems on antimicrobials
Webinar 3 – 17th November 2020: Fixing the antibiotic innovation pipeline
Mileutis Ltd., a company based in Ness Ziona, Israel raised $20 million to develop a drug that is designed to treat mastitis in cows. The private venture capital company, U.S.-based NovaQuest Capital Management LLC, which specializes in health and life sciences and oversees some $2 billion in investments, invested in the Israeli company. NovaQuest’s investment is the first of its kind in the health and life sciences sector and the first for Mileutis
Click link: Mileutis